Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 16/20 | 1.00 |
| ▸ | RARA | P10276 | 15/20 | 1.00 |
| ▸ | RARG | P13631 | 15/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.76 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.76 |
| ▸ | RXRA | P19793 | 3/20 | 0.64 |
| ▸ | RXRB | P28702 | 1/20 | 0.61 |
| ▸ | RXRG | P48443 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9374463 | 0.95 | RARA (0.90) | RARBRARARARGCYP26A1CYP26B1 | |
| SCHEMBL10835249 | 0.88 | RARB (0.79) | RARBRARARARGCYP26A1CYP26B1 | |
| SCHEMBL2391376 | 0.87 | RARB (1.00) | RARBRARARARGCYP26A1CYP26B1 | |
| SCHEMBL31266609 | 0.87 | RARB (1.00) | RARBRARARARGCYP26A1CYP26B1 | |
| SCHEMBL3453631 | 0.87 | RARB (1.00) | RARBRARARARGCYP26A1CYP26B1 | |
| Temarotene SCHEMBL8435859 | 0.85 | RARB (0.72) | RARBRARARARGCYP26A1CYP26B1 | |
| SCHEMBL10834779 | 0.85 | RARA (0.73) | RARBRARARARGCYP26A1CYP26B1 | |
| SCHEMBL18775432 | 0.85 | RARB (0.73) | RARBRARARARGCYP26A1CYP26B1 | |
| SCHEMBL12444486 | 0.85 | RARA (0.73) | RARBRARARARGCYP26A1CYP26B1 | |
| SCHEMBL29827631 | 0.84 | RARB (0.81) | RARBRARARARGCYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737566-A1 | CAS12 PROTEIN AND USE THEREOF | Reforgene Medicine (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-4692338-A1 | CAS12 PROTEIN AND USE THEREOF | Guangzhou Reforgene Medicine Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| WO-2025061113-A1 | CAS12 PROTEIN AND USE THEREOF | 广州瑞风生物科技有限公司 | 2025-03-27 | — | — | WO | claimed |
| CN-119375883-A | Multichannel SAR enhanced imaging method based on low-rank tensor decomposition | 东南大学 | 2025-01-28 | — | — | CN | claimed |
| WO-2024078645-A2 | CAS PROTEIN AND USE THEREOF | 广州瑞风生物科技有限公司 | 2024-04-18 | — | — | WO | claimed |
| CN-114841888-B | Visual data completion method based on low-rank tensor ring decomposition and factor prior | 电子科技大学 | 2023-03-28 | — | — | CN | claimed |
| CN-114841888-A | Visual data completion method based on low-rank tensor ring decomposition and factor prior | 电子科技大学 | 2022-08-02 | — | — | CN | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | claimed |
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | claimed |
| US-RE36068-E | TREATING SKIN WITH RETINOIC ACID DERIVATIVES | KLIGMAN ALBERT M (US) | 1999-01-26 | — | — | US | claimed |
| EP-0415766-B1 | Use of retinoids for reversing glucocorticoid-induced skin atrophy | ORTHO PHARMA CORP (US) | 1997-01-08 | — | — | EP | claimed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| US-5019569-A | Topical Administritation of Retinoids | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-05-28 | — | — | US | claimed |
| US-4889847-A | USED IN CONJUCTION WITH A RETINOID COMPOUND | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-12-26 | — | — | US | claimed |
| US-4888342-A | APPLYING RETINOID | KLIGMAN ALBERT M (US) | 1989-12-19 | — | — | US | claimed |
| US-4877805-A | REVERSING COLLAGEN FIBER LOSS BY APPLYING TO FACE | KLIGMAN ALBERT M (US) | 1989-10-31 | — | — | US | claimed |
| EP-0266992-A2 | Prevention of glucocorticoid-induced skin atrophy | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-05-11 | — | — | EP | claimed |
| WO-1988000466-A1 | METHODS FOR TREATMENT OF SUNDAMAGED HUMAN SKIN WITH RETINOIDS | KLIGMAN ALBERT M (US) | 1988-01-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | RARB 369/4885RARA 213/4885RARG 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.